Background: Alzheimer’s disease (AD) is often preceded by subtle cognitive, behavioral, and functional changes that emerge years before diagnosis. Clinical notes may capture these changes during care. We assessed whether AD-related signals in clinical notes were consistent across two US healthcare systems and supported prediction of future AD across settings. Methods: We conducted a cross-system validation study using longitudinal electronic health record (EHR) data from the Veterans Health Administration (VHA) and Mass General Brigham (MGB). The VHA derivation cohort included 61,537 AD cases and 234,105 matched controls; the MGB validation cohort included 2,074 AD cases and 7,054 matched controls. Using the same expert-curated AD-related keyword lexicon previously applied in VHA, we compared longitudinal keyword patterns before diagnosis across systems. We evaluated machine learning models using longitudinal keyword features within each system and directly applied VHA-trained models to MGB without retraining. Performance was compared with models using structured EHR features, including diagnosis codes, medications and abnormal laboratory measurements. Discrimination was assessed using area under the receiver operating characteristic curve (AUROC). Findings: During the 15 years preceding diagnosis, AD-related keyword frequencies increased more rapidly among individuals later diagnosed with AD than matched controls in both systems. Longitudinal case-to-control patterns were strongly correlated across systems (Spearman ρ=0·953). Across prediction horizons from 10 years to 1 day before diagnosis, random forest models using narrative keyword features achieved AUROCs of 0·542-0·756 in MGB, higher than models using structured EHR features. VHA-trained models retained measurable discrimination when applied directly to MGB (AUROC 0·533-0·706). Interpretation: Longitudinal narrative signals showed cross-system consistency and predictive value across two healthcare systems serving different patient populations, supporting their potential use for AD risk assessment while underscoring the need for local validation before clinical implementation. Funding: This research was supported by the National Institute on Aging (R01AG080670).